AIML subsidiary NeuralCloud Solutions Signs Commercial Term Sheet with Culminate H Labs to Deploy MaxYield(TM) and Insight360(TM) into INTRINSICA's DNA-Guided Biofeedback Wellness Ecosystem

Rhea-AI Summary

AIML (OTCQB:AIMLF) subsidiary NeuralCloud Solutions signed a non-binding commercial term sheet on December 9, 2025 with Culminate H Labs to integrate NeuralCloud's MaxYield™ ECG signal-processing and Insight360™ analytics into CH Labs' INTRINSICA DNA-guided biofeedback wellness platform.

The deal begins with a pilot to validate high-fidelity wearable ECG processing on smart ring devices, then intends to move toward structured commercialization with scalable per-device economics tied to CH Labs' distribution plans.

News Market Reaction

-4.00%

1 alert

-4.00% News Effect

On the day this news was published, AIMLF declined 4.00%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Reality Check

Price: $0.0278 Vol: Volume 7,690 is far below...

low vol

$0.0278 Last Close

Volume Volume 7,690 is far below the 114,291 share 20-day average, indicating limited pre-news participation. low

Technical Price at 0.0275 is trading below the 200-day moving average of 0.05.

Peers on Argus

Peers showed mixed moves: CMPD -8.68%, CRVW +5.35%, DGNMF +0.88%, while others w...

Peers showed mixed moves: CMPD -8.68%, CRVW +5.35%, DGNMF +0.88%, while others were flat, indicating stock-specific factors for AIMLF.

Historical Context

5 past events · Latest: Dec 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 09	Commercial term sheet	Positive	-4.0%	Non-binding term sheet to integrate MaxYield and Insight360 into INTRINSICA.
Dec 02	Pilot collaboration	Positive	-7.7%	Pilot with Cornerstone Physiotherapy for elite athlete cardiac performance testing.
Nov 26	Commercial term sheet	Positive	+21.1%	Equimetrics term sheet to deploy MaxYield and CardioYield in equine platforms.
Nov 11	Patent allowance	Positive	-4.7%	U.S. patent allowance covering core ECG machine-learning architecture.
Nov 04	Regulatory engagement	Positive	-0.8%	Engagement of consultants for CardioYield regulatory submission in Jamaica.

Pattern Detected

Recent positive operational updates often saw negative or muted price reactions, with only one of five news events aligning positively with price.

Recent Company History

Over the past months, AIML has focused on expanding NeuralCloud’s ECG analytics into commercial and regulatory channels. On Nov 4, 2025, it pursued Jamaican regulatory submission for CardioYield™, followed by a U.S. patent allowance on Nov 11, 2025. Subsequent non-binding commercial term sheets with Equimetrics on Nov 21, 2025 and Culminate H Labs on Dec 9, 2025, plus a pilot with Cornerstone Physiotherapy on Dec 2, 2025, highlight a consistent push toward commercialization despite mostly negative next-day price moves.

Market Pulse Summary

This announcement outlines a non-binding commercial term sheet to integrate NeuralCloud’s MaxYield™ ...

Analysis

This announcement outlines a non-binding commercial term sheet to integrate NeuralCloud’s MaxYield™ and Insight360™ into INTRINSICA, a DNA-guided biofeedback platform using wearable ECG data. It extends a series of recent pilots, commercial term sheets, and patent progress around AIML’s cardiac analytics. Investors may watch for conversion from pilot to full deployment, evidence of practitioner adoption, and any future disclosures on commercial terms or expansion beyond the initial smart ring validation phase.

Key Terms

ecg, heart rate variability, qt/qtc, st segments, +4 more

8 terms

ecg medical

"MaxYield™ ECG signal processing and Insight360™ analytics platform into CH Lab's"

An ECG (electrocardiogram) records the heart’s electrical activity through small sensors on the skin and produces a waveform that shows heart rate, rhythm and signs of stress or damage—think of it as a seismograph for the heart’s electrical signals. Investors care because ECGs are central to diagnosing and monitoring cardiac safety in clinical trials, required for regulatory approval of many drugs and devices, and drive demand for related medical equipment and services.

heart rate variability medical

"widgets that visualize metrics such as heart rate (HR), heart rate variability (HRV), QT/QTc,"

Heart rate variability (HRV) measures the tiny differences in time between successive heartbeats, reflecting how flexibly the nervous system adjusts to stress, rest, and activity. Investors watch HRV when evaluating health-related products or clinical data because higher, more responsive variability is generally a sign of good cardiovascular and autonomic health, while consistent low variability can indicate stress or illness—similar to a car that shifts smoothly versus one that struggles to change gears.

qt/qtc medical

"visualize metrics such as heart rate (HR), heart rate variability (HRV), QT/QTc, ST segments,"

QT is a measurement on an electrocardiogram that shows how long the heart takes to recharge between beats; QTc is that same measurement adjusted for heart rate so readings are comparable across people. Investors care because prolonged QT/QTc can signal a risk of dangerous irregular heartbeats and is a common reason regulators or doctors halt development or limit use of drugs, making it a key safety and regulatory metric for healthcare-related investments.

st segments medical

"HR), heart rate variability (HRV), QT/QTc, ST segments, PR intervals, and trend-based"

ST segments are the flat portions on an electrocardiogram (ECG) tracing that occur between the main heartbeat spike and the heart’s recovery wave; they act like the brief pause between two steps in a rhythm. Changes such as elevation or depression of ST segments are key signals of heart muscle injury, reduced blood flow, or treatment effects, and matter to investors because they can influence clinical trial outcomes, product safety profiles, regulatory decisions, and the commercial prospects of cardiovascular therapies and devices.

pr intervals medical

"QT/QTc, ST segments, PR intervals, and trend-based recovery markers."

PR intervals are a measurement on an electrocardiogram that shows how long an electrical signal takes to travel from the heart’s upper chambers to the lower chambers. Investors watch PR intervals when evaluating drugs, devices, or trial results because abnormal lengthening or shortening can signal a risk of heart rhythm problems, similar to timing how long it takes a message to pass through a relay — delays can indicate a malfunction.

qrs complexes medical

"labels ECG waveform components including P waves, QRS complexes, and T waves,"

QRS complexes are the sharp spikes seen on an electrocardiogram (ECG) that show the heart’s electrical signal when the main pumping chambers (the ventricles) contract to push blood out. They matter to investors because changes in their shape, timing or size are key signals doctors use to diagnose heart problems, judge treatment success and decide on medical devices or drugs—think of them as the engine’s tachometer for cardiovascular health.

digital therapeutics medical

"engineered to support Precision Medicine, Regenerative & Cellular Medicine, and Digital Therapeutics sectors."

Digital therapeutics are clinically proven software programs or apps designed to prevent, manage or treat medical conditions, often used alongside or instead of drugs and devices. They matter to investors because they can scale like software, require regulatory approval and payment from insurers or health systems, and thus offer potential recurring revenue, lower delivery costs and new market opportunities in healthcare — like a virtual prescription that replaces or enhances traditional treatment.

digital health twin technical

"Strengthen Digital Health Twin Architecture: INTRINSICA's health twin-powered by PIRTM-governed"

A digital health twin is a virtual, data-based copy of a person’s health that combines information from medical records, tests, wearables and sometimes genetics to model how their body might respond to treatments or lifestyle changes — like a flight simulator for an individual’s health. Investors care because these models can speed drug and device development, enable more targeted care, reduce the cost and time of clinical testing, and create new services that may generate recurring revenue.

AI-generated analysis. Not financial advice.

• This strengthens NeuralCloud's expansion into the global wellness and B2B health practitioner delivery model with high-fidelity cardiac signal processing and digital health integration.

• Partnership positions MaxYield™ as a core AI engine for next-generation smart rings and consumer cardiac monitoring into the broader INTRINSICA platform.

TORONTO, ON / ACCESS Newswire / December 9, 2025 / NeuralCloud Solutions Inc. ("NeuralCloud"), a wholly-owned subsidiary of AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), is pleased to announce that it has entered into a non-binding commercial agreement Term Sheet (the "Term Sheet") with Culminate H Labs, LLC ("CH Labs"), a biotech-life science innovation company pioneering DNA-guided precision health and genomic machine learning, to integrate NeuralCloud's proprietary MaxYield™ ECG signal processing and Insight360™ analytics platform into CH Lab's flagship INTRINSICA application.

INTRINSICA is CH Lab's digital health and biofeedback platform that combines DNA-guided genomic machine learning with continuous biosensor monitoring to deliver precision health at the practitioner level. The integration with NeuralCloud's patented cardiac analytics infrastructure will enhance INTRINSICA's capability to process high-fidelity wearable ECG data as part of its comprehensive digital health twin-enabling real-time correlation between genomic markers, metabolic states, and cardiovascular biofeedback. INTRINSICA represents a new category of digital therapeutic: a DNA-guided biofeedback wellness application engineered to support Precision Medicine, Regenerative & Cellular Medicine, and Digital Therapeutics sectors. The platform leverages Prime-Indexed Recursive Tensor Mathematics (PIRTM) as its foundational computational framework to deliver mathematically auditable, lawful genomic optimization.

Under the Term Sheet, NeuralCloud will provide Culminate H Labs with access to MaxYield™ for AI-based ECG denoising and beat-level labeling, along with Insight360™, the Company's visualization and reporting layer for ECG review, trend analysis, and automated report generation. NeuralCloud's integration allows INTRINSICA to:

1. Enhance Cardiovascular Biofeedback: Real-time, high-fidelity ECG processing from wearables feeds directly into INTRINSICA's genomic and metabolic models, enabling continuous cardiovascular analysis and intervention optimization.

2. Correlate Genetic Markers with Cardiac Phenotypes: MaxYield-processed ECG data integrates seamlessly with DNA-guided nutritional and epigenetic interventions, allowing practitioners to monitor how genomic and lifestyle modifications impact cardiac functions.

3. Strengthen Digital Health Twin Architecture: INTRINSICA's health twin-powered by PIRTM-governed recursive tensor fields-now incorporates cardiac signal intelligence, creating a unified, auditable model of genomic, metabolic, and cardiovascular state evolution.

4. Deliver Auditable, Ethically-Aligned Interventions: PIRTM's prime-indexed tensor framework ensures every clinical recommendation-from nutritional guidance to epigenetic interventions-maintains full computational traceability and compliance with ethical constraints enforced at the protocol level.

"This partnership validates our strategy to embed cardiac intelligence across precision medicine and genomic wellness," said Esmat Naikyar, President of NeuralCloud and Chief Product Officer at AI/ML Innovations. "We are no longer simply a clinical or research platform - we are now actively shaping the future of everyday cardiac insight. INTRINSICA represents the new frontier: platforms where genetic data, epigenetic markers, and continuous biosensor streams converge into unified health models."

"Smart wearables and continuous health monitoring have democratized access to physiological data," said Juan Carlos Rodriguez, CEO of CH Labs. "INTRINSICA transforms that data into genomically-informed, mathematically auditable clinical intelligence. By integrating NeuralCloud's cardiac analytics, we now deliver higher grade ECG processing combined with DNA-guided precision nutritional intervention-enabling health practitioners to transition from reactive care to truly personalized, predictive intervention."

"This Term Sheet is an important validation of NeuralCloud's relevance to the fast-moving consumer health and wearable innovation space," said Paul Duffy, Executive Chairman and CEO of AIML. "CH Labs represents the new wave of wellness innovation. By embedding MaxYield, AIML is positioning itself at the core of how biometric intelligence will be delivered to users globally."

As part of the staged rollout, the parties will begin with a pilot integration period, enabling Culminate H Labs to validate ECG processing performance across deployed smart ring devices before progressing toward full commercial deployment. Following successful validation, the parties intend to transition into structured commercialization with scalable per-device economics aligned to Culminate H Labs' national and global distribution strategy.

Insight360™ is NeuralCloud's no-code, drag-and-drop reporting and visualization platform built for the wellness, performance, and consumer health markets. The platform allows organizations to create custom cardiac and wellness dashboards using modular widgets that visualize metrics such as heart rate (HR), heart rate variability (HRV), QT/QTc, ST segments, PR intervals, and trend-based recovery markers. Reports can be generated automatically as export-ready PDFs for researchers, clinicians, or end users.

MaxYield™ is NeuralCloud's proprietary, patented AI signal-processing platform that isolates and labels ECG waveform components including P waves, QRS complexes, and T waves, producing structured, beat-by-beat interval data. Together, MaxYield™ and Insight360™ transform raw wearable ECG data into clean, quantified, and clinically interpretable outputs suitable for both wellness and regulated research environments.

About CH Labs, LLC (dba Culminate H Labs)
CH Labs is a biotech-life science company pioneering DNA-guided genomic machine learning for precision medicine, regenerative health, and digital therapeutics. The company's flagship platform, INTRINSICA, combines wearable biofeedback, continuous omics integration, and PIRTM-powered genomic intelligence to deliver auditable, ethically-aligned precision health protocols for B2B health practitioners. CH Labs specializes in epigenetic reprogramming, genome editing guidance, telomere maintenance, DNA-guided nutritional intervention, DNA- methylation optimization, AI precision health, and digital health twin architecture.

About AI/ML Innovations Inc.
AIML Innovations Inc. is a global technology company pioneering the use of artificial intelligence and neural networks to transform digital health. Our proprietary platforms leverage advanced signal processing and deep learning to convert complex biometric data into actionable clinical insights-supporting earlier diagnosis, personalized treatment, and more effective care.

AIML's shares trade on the Canadian Securities Exchange (CSE:AIML), the OTCQB Venture Market (AIMLF), and the Frankfurt Stock Exchange (42FB).

For detailed information please see AIML's website or the Company's filed documents at www.sedarplus.ca.

Contact:
Blake Fallis (778) 405-0882
On behalf of the Board of Directors:
Paul Duffy, Executive Chairman and CEO

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements - Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, including risks associated with the implementation of the Company's products and services. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including with respect to the nature and timing of future operations and the receipt of all applicable regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements.

SOURCE: AI/ML Innovations, Inc.

View the original press release on ACCESS Newswire

FAQ

What did AIML (AIMLF) announce on December 9, 2025 about NeuralCloud?

NeuralCloud signed a non-binding commercial term sheet to integrate MaxYield™ and Insight360™ into Culminate H Labs' INTRINSICA platform.

What is the immediate next step after the AIML-NeuralCloud term sheet with Culminate H Labs?

The parties will begin a pilot integration to validate ECG processing performance on deployed smart ring devices.

How will MaxYield™ and Insight360™ be used in INTRINSICA under the AIMLF deal?

MaxYield™ will provide AI ECG denoising and beat-level labeling while Insight360™ supplies visualization, trend analysis, and automated reporting.

Does the AIML (AIMLF) announcement include binding commercial terms or pricing?

No; the announcement describes a non-binding term sheet and a staged rollout with intended scalable per-device economics after validation.

What dimensions of health will the AIMLF–CH Labs integration aim to correlate in INTRINSICA?

The integration aims to correlate wearable ECG-derived cardiac phenotypes with DNA-guided genomic and metabolic models for practitioner-level biofeedback.